MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Rhea-AI Summary

MiNK Therapeutics, a biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies, announced its virtual Annual Meeting of Shareholders set for June 8, 2022, at 5:00 PM ET. Shareholders can join via a dedicated website using a control number from proxy materials, while guests can listen without a control number. The company aims to advance its pipeline of iNKT programs targeting cancer and immune-mediated diseases, with scalable and reproducible manufacturing processes.

Positive

• Advancement of iNKT cell therapies targeting cancer and immune-mediated diseases.
• Focus on scalable and reproducible manufacturing for off-the-shelf delivery.

Negative

• None.

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that its virtual-only Annual Meeting of Shareholders will be held at 5:00 PM ET on June 8, 2022.

To participate in the Annual Shareholders Meeting, shareholders should visit https://central.virtualshareholdermeeting.com/INKT2022 and enter the 16-digit control number found in their proxy materials. Guests may participate in a listen-only mode. No control number is required for guests. Registration for all attendees will start at 4:45 PM ET.

Webcast Information:

Date: Wednesday, June 8, 2022

Time: 5:00 PM ET

A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at https://central.virtualshareholdermeeting.com/INKT2022.

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact

Ethan Lovell
Chief External Affairs & Communications
339-927-1763
ethan.lovell@agenusbio.com

Media Relations

Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

When is the Annual Meeting of Shareholders for MiNK Therapeutics?

The Annual Meeting of Shareholders for MiNK Therapeutics is scheduled for June 8, 2022, at 5:00 PM ET.

How can shareholders participate in the MiNK Therapeutics Annual Meeting?

Shareholders can participate by visiting a dedicated website and entering their unique 16-digit control number from their proxy materials.

Is there a way for guests to participate in the MiNK Therapeutics Annual Meeting?

Yes, guests can participate in a listen-only mode without needing a control number.

What is the focus of MiNK Therapeutics' business?

MiNK Therapeutics focuses on the discovery and development of allogeneic iNKT cell therapies to treat cancer and immune-mediated diseases.

Where can I find more information about MiNK Therapeutics?

More information about MiNK Therapeutics can be found on their official website at https://minktherapeutics.com.